- Anti-oxidant/anti-inflamatory nanoparticles to protect the brain from excess electrophysiology and to mitigate damage post-crisis
- Characterization of the didys552 zebrafish mutant line (mutation in snc1lab gene) and set up of an efficacy drug screening assay using reference compounds
- Cell Therapy with GABAergic interneuron precursors for Early Infantil Epileptic Encephalopathies (S. Dravet, S. West y S. Stxbp1)
- Creation of a therapeutic drug monitoring (TDM) unit for the optimization of the Dravet syndrome pharmacological therapy
- Design, synthesis and pharmacological evaluation of new neuroprotective agents oriented to the tratment of Dravet syndrome
- Efecto de campos magnéticos estáticos de intensidad moderada en modelos de epilepsia y síndrome de Dravet
- The effect of beta-caryophyllene treatment in a murine model of Dravet syndrome
- The endocannabinoid system study in Dravet syndrome
- Intrinsic neuronal excitability and spontaneous 1 activity underlie cortical abnormalities upon Nr2f1/COUP-TFI deficiency
- Investigating Epilepsy by Super-resolution Imaging of Synapses and the Extracellular Space in Live Brain Tissue
- Precision Medicine in Dravet Syndrome
- Reactive Neurogenesis and Gliogenesis in a Dravet Syndrome Mouse Model
(Cannabinoides y síndrome de Dravet)
(Cannabinoides y síndrome de Dravet)
The effect of beta-caryophyllene treatment in a murine model of Dravet syndrome.
Timeline: 2 years.
Onintza Sagredo.
We want to assess, on the one hand, the acute effect of the beta-caryophyllene treatment on the occurrence of epileptic seizures and their duration in Dravet mice. On the other hand, the effect of chronic treatment on the motor and cognitive development of animals will also be assessed.
In addition, the biochemical processes and molecular mechanisms through which beta-caryophyllene is capable of producing beneficial effects in the short and long term will be studied.
Regarding the economic needs of the project:
€ 5,000 for histology, immunocytochemistry, cytometry and western studies (FLUOROJADE, primary and secondary antibodies), common reagents, drugs etc.
€ 2,000 for use of UCM Research Support Centers such as the cytometry center.
€ 2,000 for publication costs.
Fundraise: ayuda Celia Carrión Pérez de Tudela 6000€.
Entidades financiadoras
Fundación Mehue
Patrocinio de la Fundación Cajasol